The survival rate of extremely low birth weight infants (ELBW) has improved due to advances in neonatal care and new invasive therapies such as, central vascular catheters, endotracheal tubes, broad-spectrum antibiotics, parenteral nutrition or postnatal steroids. Although they are very effective in increasing the survival of these very tiny and immunocompromised babies, they also put them into high risk for fungal infections. Recently a few ELBW preterms, dying either from systemic or primary cutaneous aspergillosis have been reported in the literature.We report a preterm neonate who has died with disseminated cutaneous lesions due to primary cutaneous aspergillosis despite an early treatment with liposomal amphotericin B.
展开▼
